Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.
about
PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?Mechanisms of Resistance to PD-1 and PD-L1 Blockade.VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
P2860
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Negative immune checkpoint reg ...... metastatic melanoma patients.
@en
Negative immune checkpoint reg ...... metastatic melanoma patients.
@nl
type
label
Negative immune checkpoint reg ...... metastatic melanoma patients.
@en
Negative immune checkpoint reg ...... metastatic melanoma patients.
@nl
prefLabel
Negative immune checkpoint reg ...... metastatic melanoma patients.
@en
Negative immune checkpoint reg ...... metastatic melanoma patients.
@nl
P2093
P2860
P50
P1433
P1476
Negative immune checkpoint reg ...... n metastatic melanoma patients
@en
P2093
James S Wilmott
John F Thompson
Louise A Jackett
Matteo S Carlino
Robyn P M Saw
Tuba N Gide
P2860
P2888
P304
P356
10.1038/MODPATHOL.2017.89
P577
2017-08-04T00:00:00Z